PT - JOURNAL ARTICLE AU - Sears, James AU - Villas-Boas, J. Miguel AU - Villas-Boas, Vasco AU - Villas-Boas, Sofia Berto TI - Are we #stayinghome to Flatten the Curve?<sup>*</sup> AID - 10.1101/2020.05.23.20111211 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.23.20111211 4099 - http://medrxiv.org/content/early/2020/06/20/2020.05.23.20111211.short 4100 - http://medrxiv.org/content/early/2020/06/20/2020.05.23.20111211.full AB - The recent spread of COVID-19 across the U.S. led to concerted efforts by states to “flatten the curve” through the adoption of stay-at-home mandates that encourage individuals to reduce travel and maintain social distance. Combining data on changes in travel activity with COVID-19 health outcomes and state policy adoption, we characterize nationwide changes in mobility patterns, isolate the portion attributable to statewide mandates, and link these reductions to changes in COVID-19 health outcomes. We find evidence of dramatic nationwide declines in mobility prior to any statewide mandates, beginning early in a state’s outbreak. Once states adopt a mandate, we estimate further mandate-induced declines between 2.8 and 6.5 percentage points across methods. Using previous changes in mobility, we find significant effects on current mortality and morbidity, with 1% reductions in visits to non-essential businesses weeks prior being associated with 9.2 fewer deaths per 100 million per day, corresponding with over 74,000 lives saved nationwide for the months of March and April - nearly 1.3 times the actual deaths during these months. These averted deaths correspond with estimated economic benefits between $249-$745 billion for observed behavioral changes in March and April. These estimates represent a lower bound of direct health benefits, as they do not account for spillovers or undercounting of COVID-19 mortality. Our findings indicate that statewide policies reduced travel and helped attenuate the negative consequences of COVID-19. Further, substantial reductions in mobility prior to state-level policies convey important policy implications for re-opening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used for this analysis are from Unacast, Health Data are from the COVID 19 Tracking project, and policy data from The New York Times, and COVID-19 US state policy databases.